There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|
Company |
Aug. 3 | Weekly Loss | My Watchlist |
|---|---|---|---|
|
Halozyme Therapeutics |
$4.61 | (53%) | Add |
|
Zipcar |
$6.75 | (39%) | Add |
|
Molycorp |
$11.49 | (34%) | Add |
|
Dendreon |
$4.45 | (29%) | Add |
|
RealD |
$9.87 | (23%) | Add |
Source: Barron's.
Halozyme Therapeutics was clobbered after the FDA rejected its drugs.
Zipcar went in reverse after the car-sharing service posted brutal quarterly results that missed Wall Street's top- and bottom-line targets. The leading provider of auto rentals by the hour also presented soft guidance for the current quarter.
Molycorp took a hit after stunning the market with a steep and unexpected quarterly loss. Sluggish prices for the company's rare-earth minerals are holding Molycorp back.
Cancer-drug developer Dendreon tumbled after posting a wide loss and announcing a cost-cutting plan that includes closing down one of its manufacturing facilities.
RealD screened a horror movie after posting a quarterly profit that clocked in at just a third of what analysts were expecting. Increasing costs and an unflattering mix of recycled 3-D eyewear in shipments slammed margins.
Ready for a bounce
It was a rough week for these five stocks. If you want to shake yesterday's losers and ride tomorrow's winners, a new special report reveals Motley Fool's top stock for 2012. It's free, but only for a limited time, so check it out now.
